| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 2.83 | 39.3% |
| Total Income | 2.83 | 39.3% |
| Expenditure | 27.83 | 65.6% |
| PBT | — | |
| Net Profit | -24.98 | 67.2% |
| OPM | — | |
| NPM | — | |
| EPS | -0.26 | 71.7% |
Editas Medicine Reports Q1 2026 Results; EDIT-401 on Track
05 May 2026 · 5 May, 4:38 pm
Summary
Editas Medicine reported its financial results for the first quarter of 2026. The company's cash and cash equivalents totaled $123.6 million as of March 31, 2026. The net loss attributable to common stockholders was $25.0 million, or $0.26 per share, compared to a net loss of $76.1 million, or $0.92 per share, for the same period in 2025. The company anticipates that its current cash reserves will cover operating expenses and capital expenditure needs into the third quarter of 2027.
Key Highlights
- 1
Editas Medicine reported financial results for the first quarter 2026.
- 2
Cash and cash equivalents were $123.6 million as of March 31, 2026, compared to $146.6 million as of December 31, 2025.
- 3
Net loss attributable to common stockholders was $25.0 million, or $0.26 per share, for the three months ended March 31, 2026, compared to a net loss of $76.1 million, or $0.92 per share, for the same period in 2025.
- 4
Collaboration and other research and development revenues decreased to $2.8 million for the three months ended March 31, 2026, compared to $4.7 million for the same period in 2025.
- 5
Research and development expenses decreased by $9.0 million to $17.6 million for the three months ended March 31, 2026, compared to $26.6 million for the same period in 2025.
- 6
General and administrative expenses decreased by $3.1 million to $10.2 million for the three months ended March 31, 2026, compared to $13.4 million for the same period in 2025.
- 7
The company expects that the existing cash and cash equivalents will enable the company to fund its operating expenses and capital expenditure requirements into the third quarter of 2027.
Management Comments
Gilmore O’Neill
“In the first quarter, we continued to advance EDIT-401, a potentially transformative in vivo gene editing medicine designed to treat hyperlipidemia, toward the clinic,” “We are highly encouraged by our recent preclinical safety and efficacy data, including emerging data from our GLP toxicology study, as well as data demonstrating EDIT-401’s ability to reduce multiple independent risk factors for atherosclerotic cardiovascular disease, including LDL-C, Lp(a), and ApoB, in non-human primates. Based on these data, we believe EDIT-401 has a potential best-in-class profile as a one-time treatment for hyperlipidemia, and we remain on track to initiate a first-in-human study with early human proof-of-concept data by year end.”
Informational and educational content only. Not investment advice.